P L A S T I C I N J E C T I O N M O L D E R V A R I O U S M A R K E T S & A P P L I C A T I O N S • Ability to use a color concentrate in multiple resins • Low let down ratio (LDR) • Color consistency over time • Offered versatile solution across resins and in various molding methods • Provided range of 1-3% LDRs in four standard colors • Achieved consistent color in a variety of products and markets for over 10 years Omnicolor™ Multipurpose Colorants KEY REQUIREMENTS WHY AVIENT?

Glucose Monitoring App Snapshot draft M E D I C A L D E V I C E O E M C O N T I N U O U S G L U C O S E M O N I T O R I N G S Y S T E M • Adapt to strict processing requirements of a secondary operation put in place to manufacture a new device model • Meet material size and thickness requirements while achieving desired color target • Overcome material unpredictability and sensitivity to heat, light and moisture • Minimize impact of supply chain instability and changes • Offered support for processing under low pressure conditions and at every stage of manufacturing • Performed extensive R&D work to consistently deliver the customer’s color target of a hard-to-achieve light gray • Effectively addressed all material challenges and sensitivities • Provided regular ‘summaries of understanding’ to keep up with changing forecasts and ordering patterns Mevopur™ Pre-color Formulation KEY REQUIREMENTS WHY AVIENT?

Surgical instrument oem S U RG I C A L I N S T RU M E N T O E M E N D O S C O P E C O M P O N E N T S • Functional differentiation • ISO 10993 compliance • Excellent resistance to steam sterilization • Excellent chemical resistance • Delivered a variety of bright, distinguishing color choices for functional differentiation • Minimized color deviation • Provided a biocompatible solution • Offered low MOQ with flexible supply Transcend Premier PPSU Healthcare Pre- colored Solutions KEY REQUIREMENTS WHY AVIENT?

M E D I C A L E Q U I P M E N T M A N U FA C T U R E R C L O S E D S Y S T E M D R U G T R A N S F E R D E V I C E • A new material for a seal inside the next generation of closed system drug transfer device • Compliance with stringent regulatory standards: • Biocompatibility to ISO10993 • USP VI compliance • Provided regulatory support services and expertise throughout extensive medical approval process • Provided a custom formulation compliant with the highest healthcare regulatory standards • Enabled material to be manufactured and shipped globally Custom Versalloy™ HC 9220-90 Formulation KEY REQUIREMENTS WHY AVIENT?

W I R E L E S S P OW E R BA N K M A N U FAC T U R E R W I R E L E S S P O W E R B A N K • Excellent overmolding to PC/ABS • Good stain resistance and UV resistance • Easy processing • Silky Feel • Developed a customized TPE that exhibited better bonding and UV performance than the competition, and met all specification requirements • Supplied a pre-colored formulation to simplify processing and achieve desired look and feel Customized Versaflex™ CE 3120-65 KEY REQUIREMENTS WHY AVIENT?

C a s e S t u d y T h e P D I D i f f e r e n c e Characterizing the polymer’s viscoelastic properties under conditions that simulate the human body helped PDI to predict creep performance, which identifies the measurable strain put on a polymer over a given period of time. Asset No. 76593C M Y K PDICaseStudy.indd REMAY 76593 trim: 8.5in x 11in and 8.25in x 11.6875in bleed: 8.75in x 11.9375in Digital/IAM 8 . 5 i n 11 .6 8 7 5 in 8 . 7 5 i n 11 .9 3 7 5 in 8 . 2 5 i n 11 in w w w. p o l y m e r d i a g n o s t i c s . c o m Copyright © 2008, Polymer Diagnostics Inc. D e l i v e r i n g R e a l - Wo r l d R e s u l t s Research, development, and optimization of the Freedom® Lumbar Disc will help millions of patients across the world suffering from chronic back pain.

AVIENT CORPORATION F I R S T Q U A R T E R 2 0 2 3 R E S U L T S (NYSE: AVNT) M A Y 3 , 2 0 2 3 D I S C L A I M E R Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 32 79 87 83 81 76 73 90 79 77 76 73 69 60 22 A vi e n t K W R P P G F U L A V Y R P M F M C C E H X L A S H E C L H U N E M N S C L M U LT I P L E E X PA N S I O N Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of April 28, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.51. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 33 EV / 2023E EBITDA Historic Multiple 6.5 8.3 9.9 14.6 13.7 13.0 11.9 8.8 18.7 17.4 11.8 10.0 9.7 9.1 8.0 7.9 A vi e n t (2 0 1 1 ) A vi e n t (2 0 1 8 ) A vi e n t (2 0 2 3 ) K W R P P G R P M A V Y F U L E C L H X L F M C A S H S C L C E E M N H U N Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

MC-61753PE ORANGE MC-61796PP MOLLY ORANGE 1.5% MC-61797PP PRIMARY ORANGE

TIER 1 SUPPLIER S E A T B U C K L E S Y S T E M • Rapid development of 3 colors for global OEM platform, for 3 materials (POM, SAN, PP) • Help Tier 1 transition from printing to laser marking of buckles • Develop formulation that offers laser marking solution plus color • Quick reaction to develop three colors for this global vehicle launch • Smartbatch™ color + laser marking formulation met requirements for critical safety components Smartbatch™ Combination Colorants & Additives KEY REQUIREMENTS WHY AVIENT?

AVIENT CORPORATION S E C O N D Q U A R T E R 2 0 2 3 R E S U L T S (NYSE: AVNT) J U L Y 2 7 , 2 0 2 3 D I S C L A I M E R Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. expectations: US & Canada LATAM EMEA Asia • Net price benefit remains greater than wage and energy inflation • Clariant synergies and reduced administrative costs Q2 2 023 SEQUENTI AL SAL ES BY REGI ON Q 2 2 0 2 3 v s . Avient reflects 2023 adjusted EBITDA guidance of $525M and estimated run-rate CAPEX of $110M. 2023E (%) 23 79 90 84 83 76 73 88 82 77 74 72 67 57 20 A vi e n t K W R P P G F U L A V Y R P M F M C C E H X L E C L A S H H U N E M N S C L Avient Specialty Formulators Other Specialty / Chemical Companies MULTI PL E EX PANSION Source: Peer data per Bloomberg as of July 21, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $525M and closing share price of $40.93.